Thermo Fisher Scientific Inc. (NYSE:TMO) Shares Sold by Lowe Brockenbrough & Co. Inc.

Lowe Brockenbrough & Co. Inc. cut its stake in Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 2.4% in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 31,225 shares of the medical research company's stock after selling 754 shares during the period. Thermo Fisher Scientific accounts for about 1.0% of Lowe Brockenbrough & Co. Inc.'s portfolio, making the stock its 23rd largest position. Lowe Brockenbrough & Co. Inc.'s holdings in Thermo Fisher Scientific were worth $16,257,000 as of its most recent filing with the Securities & Exchange Commission.

Several other large investors also recently bought and sold shares of the stock. Geode Capital Management LLC lifted its stake in shares of Thermo Fisher Scientific by 1.7% during the third quarter. Geode Capital Management LLC now owns 7,659,943 shares of the medical research company's stock worth $4,719,477,000 after buying an additional 127,564 shares during the period. Coldstream Capital Management Inc. raised its stake in Thermo Fisher Scientific by 11.4% in the 3rd quarter. Coldstream Capital Management Inc. now owns 9,705 shares of the medical research company's stock worth $5,972,000 after acquiring an additional 995 shares during the last quarter. Greenwood Gearhart Inc. grew its stake in Thermo Fisher Scientific by 9.8% during the 3rd quarter. Greenwood Gearhart Inc. now owns 20,579 shares of the medical research company's stock valued at $12,730,000 after purchasing an additional 1,837 shares during the last quarter. Nordea Investment Management AB increased its holdings in shares of Thermo Fisher Scientific by 23.6% in the fourth quarter. Nordea Investment Management AB now owns 55,452 shares of the medical research company's stock valued at $28,868,000 after purchasing an additional 10,606 shares during the period. Finally, S.E.E.D. Planning Group LLC raised its stake in shares of Thermo Fisher Scientific by 6.2% in the fourth quarter. S.E.E.D. Planning Group LLC now owns 10,626 shares of the medical research company's stock worth $5,528,000 after purchasing an additional 618 shares during the last quarter. Hedge funds and other institutional investors own 89.23% of the company's stock.

Remove Ads

Wall Street Analysts Forecast Growth

Several equities analysts recently weighed in on TMO shares. Scotiabank increased their price target on shares of Thermo Fisher Scientific from $605.00 to $650.00 and gave the stock a "sector perform" rating in a report on Monday, February 3rd. Royal Bank of Canada set a $693.00 target price on shares of Thermo Fisher Scientific in a report on Friday, January 31st. Sanford C. Bernstein upgraded Thermo Fisher Scientific from a "market perform" rating to an "outperform" rating and set a $630.00 price objective on the stock in a research report on Friday, January 10th. StockNews.com raised shares of Thermo Fisher Scientific from a "hold" rating to a "buy" rating in a report on Tuesday, January 14th. Finally, Raymond James reissued an "outperform" rating and set a $667.00 target price (up from $650.00) on shares of Thermo Fisher Scientific in a research note on Monday, February 3rd. Four equities research analysts have rated the stock with a hold rating and nineteen have assigned a buy rating to the stock. According to MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus target price of $653.23.

Insider Activity

In other Thermo Fisher Scientific news, SVP Michael A. Boxer sold 3,775 shares of the business's stock in a transaction dated Monday, March 10th. The shares were sold at an average price of $532.52, for a total transaction of $2,010,263.00. Following the sale, the senior vice president now directly owns 10,816 shares in the company, valued at $5,759,736.32. This represents a 25.87 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Stephen Williamson sold 9,825 shares of the firm's stock in a transaction that occurred on Tuesday, February 4th. The shares were sold at an average price of $585.59, for a total transaction of $5,753,421.75. Following the completion of the transaction, the chief financial officer now directly owns 27,296 shares of the company's stock, valued at approximately $15,984,264.64. The trade was a 26.47 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 23,900 shares of company stock valued at $13,106,062. Company insiders own 0.34% of the company's stock.

Thermo Fisher Scientific Trading Down 1.2 %

Shares of NYSE TMO traded down $6.13 during midday trading on Tuesday, reaching $513.77. 1,170,740 shares of the stock were exchanged, compared to its average volume of 1,538,611. The stock has a market capitalization of $193.83 billion, a P/E ratio of 31.08, a PEG ratio of 2.99 and a beta of 0.79. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.29 and a current ratio of 1.66. The company has a 50 day simple moving average of $545.44 and a 200 day simple moving average of $554.91. Thermo Fisher Scientific Inc. has a twelve month low of $493.30 and a twelve month high of $627.88.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last posted its earnings results on Thursday, January 30th. The medical research company reported $6.10 EPS for the quarter, beating analysts' consensus estimates of $5.94 by $0.16. Thermo Fisher Scientific had a return on equity of 17.51% and a net margin of 14.78%. As a group, equities analysts expect that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current year.

Thermo Fisher Scientific Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, April 15th. Shareholders of record on Friday, March 14th will be given a dividend of $0.43 per share. The ex-dividend date is Friday, March 14th. This is a boost from Thermo Fisher Scientific's previous quarterly dividend of $0.39. This represents a $1.72 dividend on an annualized basis and a dividend yield of 0.33%. Thermo Fisher Scientific's dividend payout ratio (DPR) is currently 10.41%.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.